Biotech in 2025: Investment Trends, Congress, and Approvals
In this year-in-review episode, we break down key biotech investment trends from 2025, major policy developments in Congress, and what they mean for innovation and patients. The conversation covers defense-related biotech priorities, healthcare affordability challenges, PBM reform efforts, and capital access for early-stage companies. We also preview new data on venture investment, emerging therapeutic areas, and AI-enabled drug development. The episode closes with a look at recent FDA approvals that highlight real progress reaching patients.
What stood out to you most in the 2025 biotech…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.